Sumatriptan in migraine.

Sumatriptan iontophoretic patch for migraine.

Sumatriptan delivered in an electric patch form applied to the skin was approved by the Federal Drug Administration (FDA) in 2013 for the acute treatment of migraine. About 25 years ago, sumatriptan was the first drug in the medication class of triptans to be approved for the treatment of migraine. Sumatriptan already comes in a tablet, injectable form, nasal spray, and in at least 14 countries...

Intranasal sumatriptan for migraine in children.

QUESTION I am seeing more and more children and adolescents with headaches that can be defined as migraine headache. I have read about intranasal sumatriptan as an abortive therapy. Is this an effective treatment? ANSWER Acute migraine headache among children and adolescents is common and treatment is challenging. Intranasal sumatriptan is a safe and mostly effective option for children and a...

Treatment of acute migraine with subcutaneous sumatriptan.

Sumatriptan succinate, a 5-HT1D receptor agonist, constricts human cranial arteries. Two parallel-group trials for treatment of acute migraines were conducted in the United States. Adult patients were randomized and given either 6 mg of sumatriptan succinate subcutaneously (n = 734) or placebo (n = 370). At 1 hour, sumatriptan was significantly more effective than placebo in reducing moderate o...

Sumatriptan: efficacy and contribution to migraine mechanisms.

DRUG PROFILE Update on sumatriptan: new progress in migraine treatment

10.2217/14750708.2.3.349 © 2 part of The introduction of the 5-HT1B/1D agonist sumatriptan in 1991 marked a significant advance in the management of migraine. Sumatriptan was the first migraine pharmacotherapy designed to selectively target the neurovascular origin of migraine pain. Sumatriptan was introduced in several formulations – injection, nasal spray, conventional tablet or suppository. ...